7 Hills Pharma

7 Hills Pharma LLC, founded with a mission to innovate in the field of immuno-oncology, focuses on developing drugs to treat drug-resistant cancers and enhance the effectiveness of existing cancer therapies. The company aims to address the unmet needs in treating solid tumors such as lung and colon cancers, which have not seen the same success rates as rare cancers with current immunotherapies. Their core products include cost-effective technologies that modulate the immune system to improve immune checkpoint blockade, adoptive cell therapy, and cord blood transplant treatments.

Notable figures affiliated with 7 Hills Pharma include Lionel D. Lewis, who serves as the Chief Medical Officer. The company has achieved significant milestones, including the FDA clearance of their investigational new drug application for 7HP349, a first-in-class immune stimulant. Additionally, they have formed a scientific advisory board comprising prominent immuno-oncology experts to guide their integrin activator program. The overall impact of 7 Hills Pharma lies in its potential to significantly enhance cancer treatment outcomes and address critical gaps in current therapies for solid tumors and rare genetic diseases.